EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR ‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker

Meejeong Kim, Gyeong Sin Park, Kyo Young Lee iD, Seok Whan Moon, Yeoun Eun Sung iD

Thoracic Cancer · 2025-04 · 16 (7)

DOI: 10.1111/1759-7714.70058 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2025-04. Verfasst von Meejeong Kim und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Tumor Suppressor Protein p53, Lung Neoplasms, Mutation. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Non‐small cell lung carcinoma (NSCLC) is a leading cause of cancer‐related mortality, with recurrence risks posing significant challenges in early‐stage disease management. While epidermal growth factor receptor (EGFR) mutations are common, the role of concurrent genetic alterations remains underexplored, and findings have often been inconsistent, particularly in early‐stage tumors.

Methods

We retrospectively analyzed 424 EGFR‐mutated NSCLC patients diagnosed from 2017 to 2022. Next‐generation sequencing (NGS) was used to identify genetic alterations, and immunohistochemistry (IHC) was employed to correlate TP53 mutations and EGFR amplification with protein expression. Survival outcomes were assessed using Kaplan–Meier and Cox regression analyses, while predictive cutoffs were determined with receiver operating characteristic (ROC) curve analysis.

Results

TP53 mutations and EGFR amplification were more prevalent in Stages 2–4 compared to Stage 1 ( p < 0.001 and 0.005, respectively). In Stage 1, TP53 mutations, particularly exon 4 and frameshift/nonsense types, were associated with worse overall survival (OS) and disease‐free survival (DFS). EGFR amplification was linked to shorter DFS in Stage 1 ( p = 0.006). Both alterations correlated with aggressive pathological features, including advanced N stage, lymphovascular invasion, and high histological grade. IHC cutoffs of 15% for TP53 and H ‐score ≥ 180 for EGFR amplification demonstrated high predictive accuracy (AUC = 0.981 and 0.936, respectively).

Conclusion

Specific subtypes of TP53 mutations and EGFR amplification are important prognostic markers in early‐stage NSCLC. IHC offers a practical surrogate for genetic testing, aiding in risk stratification and guiding adjuvant therapy decisions for high‐risk patients. Larger validation studies are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungTumor Suppressor Protein p53Lung NeoplasmsMutationBiomarkers, TumorHumansMaleFemaleErbB ReceptorsMiddle AgedRetrospective StudiesImmunohistochemistryAgedAdultPrognosisNeoplasm StagingAged, 80 and overRisk AssessmentGene Amplification

Stichwörter der Autor:innen

EGFR amplificationEGFR mutationTP53 mutationearly‐stage lung cancernon‐small cell lung cancer (NSCLC)

Substanzen

ErbB ReceptorsEGFR protein, humanTumor Suppressor Protein p53Biomarkers, TumorTP53 protein, human

Autor:innen und Institutionen

  • Department of Hospital Pathology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Department of Thoracic and Cardiovascular Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.

ORCID-Profile: Kyo Young Lee, Yeoun Eun Sung

Zitieren

APA

Kim, M., Park, G. S., Lee, K. Y., Moon, S. W., & Sung, Y. E. (2025). Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR ‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker. Thoracic Cancer, 16(7). https://doi.org/10.1111/1759-7714.70058

Vancouver

Kim M, Park GS, Lee KY, Moon SW, Sung YE. Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR ‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker. Thoracic Cancer. 2025;16(7). doi:10.1111/1759-7714.70058

BibTeX
@article{Kim2025,
  author = {Kim, Meejeong and Park, Gyeong Sin and Lee, Kyo Young and Moon, Seok Whan and Sung, Yeoun Eun},
  title = {Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR ‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker},
  journal = {Thoracic Cancer},
  year = {2025},
  volume = {16},
  number = {7},
  doi = {10.1111/1759-7714.70058}
}
Kostenlos starten →